GMABC Stock Overview

A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. More details

GMABC fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	6/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 81.6% below our estimate of its fair value

Earnings are forecast to grow 13.71% per year

Earnings grew by 80.2% over the past year

Risk Analysis

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Genmab A/S Competitors

Bioventix

AIM:BVXP

UK£143.7m

PureTech Health

LSE:PRTC

UK£302.6m

Hikma Pharmaceuticals

LSE:HIK

UK£4.4b

HUTCHMED (China)

AIM:HCM

UK£1.9b

Price History & Performance

Summary of share price highs, lows and changes for Genmab
Historical stock prices
Current Share Price	DKK 1,377.00
52 Week High	DKK 2,060.00
52 Week Low	DKK 1,295.25
Beta	0.90
1 Month Change	0.25%
3 Month Change	-0.61%
1 Year Change	-31.18%
3 Year Change	-33.51%
5 Year Change	-30.19%
Change since IPO	2,960.00%

Recent updates

Shareholder Returns

	GMABC	GB Biotechs	GB Market
7D	6.3%	5.1%	0.9%
1Y	-31.2%	-15.3%	0.3%

Return vs Industry: GMABC underperformed the UK Biotechs industry which returned -11.8% over the past year.

Return vs Market: GMABC underperformed the UK Market which returned 1.1% over the past year.

Price Volatility

Is GMABC's price volatile compared to industry and market?
GMABC volatility
GMABC Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.8%
Market Average Movement	5.7%
10% most volatile stocks in GB Market	10.9%
10% least volatile stocks in GB Market	3.1%

Stable Share Price: GMABC's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine GMABC's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1998	2,682	Jan G.J. de Winkel	www.genmab.com

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors.

Genmab A/S Fundamentals Summary

How do Genmab's earnings and revenue compare to its market cap?
GMABC fundamental statistics
Market cap	DKK 84.92b
Earnings (TTM)	DKK 7.84b
Revenue (TTM)	DKK 21.53b

10.8x

P/E Ratio

3.9x

P/S Ratio

Is GMABC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GMABC income statement (TTM)
Revenue	DKK 21.53b
Cost of Revenue	DKK 985.00m
Gross Profit	DKK 20.54b
Other Expenses	DKK 12.70b
Earnings	DKK 7.84b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 08, 2025

Earnings per share (EPS)	126.04
Gross Margin	95.42%
Net Profit Margin	36.44%
Debt/Equity Ratio	0%

How did GMABC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/07 17:20
End of Day Share Price	2025/05/07 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genmab A/S is covered by 46 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Andrew Carlsen	ABG Sundal Collier
Armelle Moulin	AlphaValue
Emily Field	Barclays

GMABC Stock Overview

Rewards

Risk Analysis

Genmab A/S Competitors

AIM:BVXP

UK£143.7m

LSE:PRTC

UK£302.6m

LSE:HIK

UK£4.4b

AIM:HCM

UK£1.9b

Price History & Performance

Recent News & Updates

Genmab A/S to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed Refractory Follicular Lymphoma

Genmab A/S Announces Japan Ministry of Health, Labour and Welfare Approves TIVDAK for the Treatment of Advanced or Recurrent Cervical Cancer

Genmab A/S Updates Data from Cohort B1 of the Phase 1/2 RAINFOL-01 Study of Rina-S

Genmab A/S, Annual General Meeting, Mar 12, 2025

Genmab A/S Provides Revenue Guidance for 2025

Genmab A/S Announces New Results from the Phase 1b/2 EPCORE NHL-2 Trial

Recent updates

Genmab A/S to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed Refractory Follicular Lymphoma

Genmab A/S Announces Japan Ministry of Health, Labour and Welfare Approves TIVDAK for the Treatment of Advanced or Recurrent Cervical Cancer

Genmab A/S Updates Data from Cohort B1 of the Phase 1/2 RAINFOL-01 Study of Rina-S

Genmab A/S, Annual General Meeting, Mar 12, 2025

Genmab A/S Provides Revenue Guidance for 2025

Genmab A/S Announces New Results from the Phase 1b/2 EPCORE NHL-2 Trial

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Executive VP & CFO recently sold kr.22m worth of stock

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Full year 2023 earnings released: EPS: kr.66.64 (vs kr.84.45 in FY 2022)

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

New minor risk - Share price stability

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings released: EPS: kr.20.80 (vs kr.28.87 in 2Q 2022)

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold kr.58m worth of stock

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought kr.796k worth of stock

Full year 2022 earnings released: EPS: kr.84.45 (vs kr.46.00 in FY 2021)

Insufficient new directors

Co-Founder recently sold kr.57m worth of stock

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Second quarter 2022 earnings released: EPS: kr.28.87 (vs kr.4.68 in 2Q 2021)